(Q36548722)

14 August 2017

1 reference

title

Developments in the pharmacotherapeutic management of osteoporosis (English)

1 reference

14 August 2017

0 references

3

Jean-Yves Reginster

1 reference

14 August 2017

Pierre Close

1

1 reference

14 August 2017

Audrey Neuprez

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

12

1 reference

14 August 2017

page(s)

1603-1615

1 reference

Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Risedronate prevents new vertebral fractures in postmenopausal women at high risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Adherence, patient preference and dosing frequency: understanding the relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: Preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Raloxifene reduces fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Parathyroid Hormone plus Alendronate — A Combination That Does Not Add Up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Parathyroid hormone (1-84) and treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Novel therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1603

10.1517/14656566.7.12.1603

21 January 2018

Identifiers

DOI

1 reference

release_al55gwa7cbcotc4ii3wi7a3mna

14 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/al55gwa7cbcotc4ii3wi7a3mna

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference